Allogene Therapeutics, Inc. (NASDAQ:ALLO) produced a 29.67% rally since recording the worst price of $21.67. Thanks to the latest 2.82% increase, it now trades at $28.1. Throughout the trading on 01/10/2019, the share price floated between $26.76 and $28.83. This company shares are 19.82% off its target price of $33.67 and the current market capitalization stands at $3.55B. The recent change has given its price a 3.67% lead over SMA 50 and -20.96% deficit over its 52-week high. The stock witnessed 5.96% gains, 0% declines and 0% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found ALLO’s volatility during a week at 5.7% and during a month it has been found around 7.02%.Allogene Therapeutics, Inc. (NASDAQ:ALLO) Insider Trades
Multiple company employees have indulged in significant insider trading. Allogene Therapeutics, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that 10% Owner Tpg Group Holdings (Sbs) Advis has acquired 675,000 shares of Allogene Therapeutics, Inc. (ALLO) in trading session dated Oct. 15, 2018. These shares are worth $12,150,000 and were traded at $18 each. The SEC filing shows that Pfizer Inc performed a purchase of 55,556 shares. The 10% Owner added these shares by way of transaction on Oct. 15, 2018. The company’s shares were assimilated at $18 per share worth to an investment of some $1,000,008 on account of Pfizer Inc.
Director, 10% Owner, Belldegrun Arie, purchased 35,000 common shares of Allogene Therapeutics, Inc. (ALLO) in the open market. In a transaction dated Oct. 15, 2018, the shares were bought at an average price of $18, giving away a sum of $630,000. After this purchase, 11,719,944 common shares of ALLO are directly owned by the insider, with total stake valued at $329,330,426.
In the transaction dated Oct. 15, 2018, the great number of shares acquired came courtesy the President and CEO; Chang David D added a total of 40,000 shares at an average price of $18, amounting to approximately $720,000. The insider now directly owns 4,793,507 shares worth $134,697,547.Allogene Therapeutics, Inc. (ALLO) Analyst Guide
Several analysts have released their opinion on Allogene Therapeutics, Inc. (NASDAQ:ALLO), with 1 analysts believing it is a strong buy. Whereas 1 of them predict the stock is a hold. Also, there are 2 buy, 0 sell and 0 strong sell ratings, collectively assigning a 2 average brokerage recommendation.